UK Markets closed

Aladdin Healthcare Technologies SE (NMI.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
0.3700-0.0300 (-7.50%)
At close: 3:51PM CEST
Full screen
Previous close0.4000
Open0.3600
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.3600 - 0.3990
52-week range0.3600 - 4.4200
Volume12,550
Avg. volume4,652
Market cap3.922M
Beta (5Y monthly)0.19
PE ratio (TTM)N/A
EPS (TTM)-0.2610
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    Aladdin Healthcare Technologies jointly develops AI-Platform for Cardiovascular Diseases that achieves three Patents in China

    DGAP-News: Aladdin Healthcare Technologies SE / Key word(s): Patent/Miscellaneous24.02.2021 / 07:59 The issuer is solely responsible for the content of this announcement.Aladdin Healthcare Technologies jointly develops AI-Platform for Cardiovascular Diseases that achieves three Patents in China - Aladdin has developed patented AI-platform together with its partner IIAT in China- The innovative AI-driven platform marks a turning point in the early diagnostics of heart diseases- Next step is gaining patent approval also in the USA and EuropeBERLIN/LONDON February 24, 2021 - Aladdin Healthcare Technologies SE ("Aladdin", ISIN: DE000A12ULL2), a leading developer of Artificial Intelligence (AI) based healthcare diagnostics and drug discovery applications, has developed together with its partner IIAT (Imperial Institute of Advanced Technology) an innovative AI-powered data analysis platform for cardiovascular diseases. The platform has just successfully gained three patents in China.Aladdin achieves a milestone in the early diagnostics of cardiovascular diseases. By combining multimodal data specifically integrated AI-driven blood analysis, the Company brings a novel approach of early diagnostics to market. Moreover, most other currently available AI approaches reflect the reliance of the industry on utilising cardiac images as a singular approach methodology. This is only adequate for basic diagnosis and does not approach the multiple complexities that involve the disease and its underlying pathways.The AI-data platform has gained three patents in China that include:a. Automated Multimodal Cardiac Image Analysis, Visualisation and 3D Printingb. Multiscale Auto-focused Super-resolutionc. High-resolution Myocardial Motion Analysis SystemThe IIAT has been established by a team of royal academicians and professors from Imperial College London and Royal Brompton Hospital. It is a new research and development institute engaging the international exchange and cooperation in science and technology, Chinese-European technology transfer, and research in medical imaging technology. It is also committed to bringing human resources, technologies as well as projects in the field of healthcare from Europe to China and promoting them in China.Wade Menpes-Smith, CEO of Aladdin Healthcare Technologies, comments: "The achievement of three patents in China is a further acknowledgment of our ability in improving the world of healthcare diagnostics with our expertise and together with our important network of international partners." Under the agreement with IIAT, Aladdin has all international rights to license the AI-technology in Europe, UK and the USA, but not in China. The Company is planning to seek patent approval in the USA and Europe as next step.As part of the new international growth strategy, Aladdin will list its shares on the OTC market in the USA.About Aladdin Healthcare Technologies SEAladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin Healthcare Technologies Ltd.) is a leading developer of AI healthcare diagnostics and drug discovery applications that can accelerate both early stage disease diagnosis and the end-to-end drug discovery process. Aladdin targets age-related diseases including a significant focus on Alzheimer's disease. Aladdin accomplishes this by collaborating with numerous partners within the global healthcare ecosystem to confidentially and securely gather targeted data including genome, tabular, MRI, PET, cognition and other lifestyle data. These datasets are then analysed by our award-winning AI team and used to develop proprietary AI tools that can assist healthcare professionals to more accurately and efficiently diagnose age-related diseases. This new diagnostic process will save significant time and costs for healthcare professionals. Additionally, our AI drug discovery platform will be used by pharmaceutical Companies to speed up drug development, clinical trials and predict outcomes more accurately.Website Link: www.aladdinid.comGSIN: A12ULLISIN: DE000A12ULL2TICKER SYMBOL: NMIFor further information:Aladdin Healthcare Technologies Ltd.24-26 Baltic Street WestLondon EC1Y 0URPhone +44 7714 719696Email: info@aladdinid.comContact PressCROSS ALLIANCE communication GmbHSara PintoPhone +49 89 1250 90330Email: pi@crossalliance.dewww.crossalliance.de24.02.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: Aladdin Healthcare Technologies SE Unter den Linden 10 10117 Berlin Germany Phone: 030 700140449 E-mail: info@aladdinid.com Internet: www.aladdinid.com ISIN: DE000A12ULL2 WKN: A12ULL Listed: Regulated Market in Dusseldorf EQS News ID: 1170650 End of News DGAP News Service

  • EQS Group

    Aladdin Healthcare Technologies signs Agreement to build proprietary Genomic Data Blockchain Platform with Zero Knowledge Proof

    DGAP-News: Aladdin Healthcare Technologies SE / Key word(s): Letter of Intent/Alliance22.01.2021 / 09:10 The issuer is solely responsible for the content of this announcement.Aladdin Healthcare Technologies signs Agreement to build proprietary Genomic Data Blockchain Platform with Zero Knowledge ProofBERLIN/LONDON January 22, 2021 - Aladdin Healthcare Technologies SE ("Aladdin", ISIN: DE000A12ULL2), a leading developer of Artificial Intelligence (AI) based healthcare diagnostics and drug discovery applications, has signed a Memorandum of Understanding (MOU) with Consentia Ltd, with the goal of building a Blockchain platform based on Zero Knowledge Proof (ZKP) for safely sharing genomics and multi-omics data.Since genomic data analysis is growing in prominence for precision diagnosis and medicine, the need for fast and secure sharing of such data is increasing worldwide and requires appropriate tools to ensure people's data privacy. Aladdin will build a ZKP-based blockchain platform to gather global healthcare data with Consentia, an innovative blockchain development start-up in the UK and Hongkong, led by Paul Sitoh, one of the most sought-after experts in blockchain technology and co-builder of Hyperledger Fabric.Nowadays, the healthcare industry is dominated by a lot of time-consuming due diligence based on privacy issues. Zero Knowledge Proof (ZKP) is a cryptography method by which data can be proven without actually showing or sharing any additional information. Both, Aladdin and Consentia will collaborate to build a proprietary data-tool based on ZKP for eradicating passwords and protecting the identities of global patients that submit multi-omics and genetic healthcare data to centralized databases. Furthermore, the parties will develop a new blockchain platform based on the ZKP-tool where users and healthcare professionals will be able to safely access and store the healthcare data.Wade Menpes-Smith comments: "Aladdin has taken a massive step in the field of Blockchain applications for Healthcare by signing this Agreement. We are more than happy to have Consentia at our side as valuable partner in this important challenge. We want to protect people's identities while giving our innovative contribution to medical research. This is a big chance for expanding our business opportunities by commercializing the platform in the future with existing and new partners at a global level."About Aladdin Healthcare Technologies SEAladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin Healthcare Technologies Ltd.) is a leading developer of AI healthcare diagnostics and drug discovery applications that can accelerate both early stage disease diagnosis and the end-to-end drug discovery process. Aladdin targets age-related diseases including a significant focus on Alzheimer's disease. Aladdin accomplishes this by collaborating with numerous partners within the global healthcare ecosystem to confidentially and securely gather targeted data including genome, tabular, MRI, PET, cognition and other lifestyle data. These datasets are then analysed by our award-winning AI team and used to develop proprietary AI tools that can assist healthcare professionals to more accurately and efficiently diagnose age-related diseases. This new diagnostic process will save significant time and costs for healthcare professionals. Additionally, our AI drug discovery platform will be used by pharmaceutical Companies to speed up drug development, clinical trials and predict outcomes more accurately.Website Link: www.aladdinid.comGSIN: A12ULLISIN: DE000A12ULL2TICKER SYMBOL: NMIFor further information:Aladdin Healthcare Technologies Ltd.24-26 Baltic Street WestLondon EC1Y 0URPhone +44 7714 719696Email: info@aladdinid.comContact PressCROSS ALLIANCE communication GmbHSara PintoPhone +49 89 1250 90330Email: pi@crossalliance.dewww.crossalliance.de22.01.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: Aladdin Healthcare Technologies SE Unter den Linden 10 10117 Berlin Germany Phone: 030 700140449 E-mail: info@aladdinid.com Internet: www.aladdinid.com ISIN: DE000A12ULL2 WKN: A12ULL Listed: Regulated Market in Dusseldorf EQS News ID: 1162478 End of News DGAP News Service

  • EQS Group

    Aladdin Healthcare Technologies SE reports preliminary figures for financial year 2019 and readjustment of the 2018 financial year figures

    Aladdin Healthcare Technologies SE / Key word(s): Preliminary ResultsAladdin Healthcare Technologies SE reports preliminary figures for financial year 2019 and readjustment of the 2018 financial year figures08-Dec-2020 / 12:07 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Aladdin Healthcare Technologies SE reports preliminary figures for financial year 2019 and readjustment of the 2018 financial year figuresAladdin Healthcare Technologies SE (the "Company") reports that in the course of the preparation of its consolidated annual financial statements under IFRS for the financial year 2019, losses in the amount of EUR 2,989.9k will be accounted for due to an EUR 1,532.2k impairment of financial assets. In 2018 there has been a re-adjustment of expenses relating to intellectual property that were originally deemed by the Company as being eligible for capitalisation in the balance sheet. These losses in the amount of EUR 1,430.6k together with losses from operational activities presumably result in total losses for the financial year 2018 in the amount of EUR 5,391.4. The Company is currently in the process of finalising the financial statements for 2019 which are expected to be approved by the Board of Directors and audited by its auditor after the first two weeks of December.In 2019 the losses from impairment of assets relate to non-current loans, which is in majority made up of a convertible loan to the Hong Kong licensee of the Company. An impairment charge of EUR 1,532.2k will be applied to the loan as management made the decision not to pursue the terms of the license any further and to cease expenditure on any future development with the Shenzhen Guo Yi Hui Hospital Management Co. The loan is not reasonably recoverable at the balance sheet date, therefore an impairment charge for the full outstanding amount has been applied through the profit and loss. The impairment charge in the amount of EUR 1,532.2k together with losses from operational activities will presumably result in total losses for the financial year 2019 of EUR 2,989.9k.The retained earnings balance before correction was EUR -3,920.4k in the financial year 2018. After correction of losses from the re-adjustment related to the capitalisation of expenses incurred in the financial year 2018 relating to the software of the Company and other smaller adjustments, the retained earnings were reduced by EUR 2.492.7k to a post adjustment balance of EUR -6.413.1k.Further preliminary key figures of the 2019 consolidated financial statements are as follows:Balance sheet:Total assets: EUR 480.5k (2018: EUR 1,919.0k)Total Equity: EUR -1,765.8k (2018: EUR 1,463.0k)Total liabilities: EUR 2,246.2k (2018: EUR 456.0k)Profit and loss:Revenues: EUR 0 (2018: EUR 174.5k)Operating loss: EUR 2,989.9k (2018: EUR 5,391.4k)Contact:Aladdin Healthcare Technologies SEUnter den Linden 1010117 BerlinTel 0307700 140 449email: info@aladdinid.comwww.aladdinid.com08-Dec-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: Aladdin Healthcare Technologies SE Unter den Linden 10 10117 Berlin Germany Phone: 030 700140449 E-mail: info@aladdinid.com Internet: www.aladdinid.com ISIN: DE000A12ULL2 WKN: A12ULL Listed: Regulated Market in Dusseldorf EQS News ID: 1153468   End of Announcement DGAP News Service